更新于：2024-11-18
Iguratimod
艾拉莫德
更新于：2024-11-18
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2011-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H14N2O6S |
InChIKeyANMATWQYLIFGOK-UHFFFAOYSA-N |
CAS号123663-49-0 |
关联
77
项与 艾拉莫德 相关的临床试验艾拉莫德片在健康受试者中的单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计空腹及餐后的人体生物等效性试验
艾拉莫德片在健康受试者中的单剂量、随机、开放、交叉、两制剂、两周期餐后人体生物等效性试验
艾拉莫德片在空腹及餐后条件下的人体生物等效性试验
100 项与 艾拉莫德 相关的临床结果
登录后查看更多信息
100 项与 艾拉莫德 相关的转化医学
登录后查看更多信息
100 项与 艾拉莫德 相关的专利（医药）
登录后查看更多信息
198
项与 艾拉莫德 相关的文献（医药）2024-12-31Renal failure
Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition
Article
作者: Xie, Tingting ; Zhang, Weiru ; Li, Zhilan ; Wang, Xuan ; Yu, Shenyi ; Zhou, Yueyuan
Iguratimod is a novel synthetic, small-molecule immunosuppressive agent used to treat rheumatoid arthritis. Through ongoing exploration of its role and mechanisms of action, iguratimod has been observed to have antifibrotic effects in the lung and skin; however, its effect on renal fibrosis remains unknown. This study aimed to investigate whether iguratimod could affect renal fibrosis progression. Three different concentrations of iguratimod (30 mg/kg/day, 10 mg/kg/day, and 3 mg/kg/day) were used to intervene in unilateral ureteral obstruction (UUO) model mice. Iguratimod at 10 mg/kg/day was observed to be effective in slowing UUO-mediated renal fibrosis. In addition, stimulating bone marrow-derived macrophages with IL-4 and/or iguratimod, or with TGF-β and iguratimod or SRC inhibitors in vitro, suggested that iguratimod mitigates the progression of renal fibrosis in UUO mice, at least in part, by inhibiting the IL-4/STAT6 signaling pathway to attenuate renal M2 macrophage infiltration, as well as by impeding SRC activation to reduce macrophage-myofibroblast transition. These findings reveal the potential of iguratimod as a treatment for renal disease.
2024-11-01SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
Efficacy and safety of iguratimod combined with celecoxib in active axial spondyloarthritis: a randomized, double-blind, placebo-controlled study
Article
作者: Wang, W ; Chen, X ; Xue, J
OBJECTIVE:
To assess the efficacy and safety of iguratimod in adult patients with active axial spondyloarthritis (axSpA).
METHOD:
This randomized, double-blind, placebo-controlled clinical trial lasted for 28 weeks. Patients with axSpA were randomized 1:1 to receive iguratimod 25 mg twice daily or a placebo. All patients also took celecoxib 200 mg twice daily for the first 4 weeks and on demand from 4 to 28 weeks. The primary endpoints were ASAS20 at 4 weeks and the non-steroidal anti-inflammatory drug (NSAID) index at 28 weeks. Other assessment variables included ASAS40, ASAS5/6 response rates, Spondyloarthritis Research Consortium of Canada (SPARCC) scores, and adverse events.
RESULTS:
In total, 35 patients completed the study and were included for analyses. The median (interquartile range) NSAID index was 43.8 (34.9-51.8) in the iguratimod group, which is significantly lower than 68.9 (42.5-86.4) in the placebo group (p = 0.025). ASAS response rates and changes in disease activity scores were similar between the iguratimod and placebo groups. Patients in the iguratimod group had more improvement in median (interquartile range) SPARCC scores for sacroiliac joints than did those in the placebo group [71% (54-100%) vs 40% (0-52%), p = 0.006]. Iguratimod combined with celecoxib was not associated with a greater risk of adverse effects than was monotherapy with celecoxib. No severe adverse events occurred.
CONCLUSIONS:
In the treatment of active axSpA, iguratimod has a potential NSAID-sparing effect, and may also reduce magnetic resonance imaging-assessed bone marrow oedema in sacroiliac joints. Iguratimod provides an additional treatment option for patients with active axSpA.Clinical trial registration numberChiCTR2000029112, Chinese Clinical Trial Registry (http://www.chictr.org.cn).
2024-10-01COLLOIDS AND SURFACES B-BIOINTERFACES
Transdermal delivery of iguratimod and colchicine ethosome by dissolving microneedle patch for the treatment of recurrent gout
Article
作者: Dong, Jindian ; Yang, Mingjing ; Zhou, Xingyu ; Liu, Shihui ; Song, Zhuoyue ; Xiong, Tong ; Chen, Chuncheng ; Li, Du ; Yan, Xiaoxia ; Li, Yanhui ; Liu, Tao ; Li, Shijie ; Xu, Nenggui
This study introduces a novel approach of repetitive modeling to simulate the pathological process of recurrent gout attacks in humans. This methodology addresses the instability issues present in rat models of gout, providing a more accurate representation of the damage recurrent gout episodes inflict on human skeletal systems. A soluble nanoneedle system encapsulating colchicine and iguratimod ethosomal formulations was developed. This system aims to modulate inflammatory cytokines and inhibit osteoclast activity, thereby treating inflammatory pain and bone damage associated with recurrent gout. Additionally, a comprehensive evaluation of the microneedles' appearance, morphology, mechanical properties, and penetration capability confirmed their effectiveness in penetrating the stratum corneum. Dissolution tests and skin irritation assessments demonstrated that these microneedles dissolve rapidly without irritating the skin. In vitro permeation studies indicated that transdermal drug delivery via these microneedles is more efficient and incurs lower drug loss compared to traditional topical applications. In vivo pharmacodynamic assessments conducted in animal models revealed significant analgesic and anti-inflammatory effects when both types of microneedles were used together. Further analyses, including X-ray imaging, hematoxylin and eosin (H&E) staining, Safranin-O/fast green staining, tartrate-resistant acid phosphatase staining, and quantification of osteoclasts, confirmed the bone-protective effects of the microneedle combination. In conclusion, the findings of this research underscore the potential of this novel therapeutic approach for clinical application in the treatment of recurrent gout.
100 项与 艾拉莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 类风湿关节炎 | 中国 | 2011-08-23 | |
| 类风湿关节炎 | 中国 | 2011-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性干燥综合征 | 临床2期 | 中国 | 2021-03-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 911 | 襯繭構簾構積襯範築夢(壓觸獵積憲夢襯製獵鏇) = 衊簾製簾製艱壓顧構壓 艱壓網鬱鏇餘夢艱餘餘 (網鹹齋製鹹蓋顧繭鑰糧 ) | 积极 | 2024-07-26 | |||
襯繭構簾構積襯範築夢(壓觸獵積憲夢襯製獵鏇) = 觸顧艱艱鏇網淵觸淵鏇 艱壓網鬱鏇餘夢艱餘餘 (網鹹齋製鹹蓋顧繭鑰糧 ) | |||||||
临床2期 | 71 | 構糧範網遞蓋觸觸襯窪(製壓鑰範選製鹽選鬱網): odds ratio = 1.82 (95% CI, 1.22 ~ 2.7), P-Value = 0.003 | - | 2023-12-10 | |||
N/A | 302 | NSAIDs only | 築餘衊襯餘膚壓製蓋繭(繭淵網齋衊願蓋鏇簾夢) = 膚築鹹鬱願餘製窪衊蓋 蓋廠願鏇獵壓糧簾製餘 (壓選鬱網衊鑰選積獵衊 ) | 积极 | 2023-05-31 | ||
NSAIDs combined with SSZ | 築餘衊襯餘膚壓製蓋繭(繭淵網齋衊願蓋鏇簾夢) = 積築餘憲築範襯顧鏇網 蓋廠願鏇獵壓糧簾製餘 (壓選鬱網衊鑰選積獵衊 ) | ||||||
N/A | - | 壓醖範構網鹽鹹醖鏇夢(淵築願衊築製積蓋齋衊) = 製選遞選蓋襯網蓋獵鏇 簾範艱鏇簾襯襯蓋遞壓 (簾淵艱構醖築鬱積簾鏇 ) 更多 | - | 2023-05-31 | |||
临床4期 | 类风湿关节炎 一线 | 246 | IGU combination with csDMARDs | 選夢選蓋衊選窪壓鏇鹽(範築窪簾積淵壓範選糧) = 醖顧遞夢窪鬱製鑰艱糧 製鹽淵醖顧繭鹹憲廠範 (壓膚壓鏇獵構窪淵壓選 ) 更多 | - | 2023-05-31 | |
N/A | - | 襯選繭衊願獵遞築夢壓(糧願鹹鹹鏇淵壓獵範遞) = 製製艱餘範夢構鬱遞鏇 鏇鬱齋淵夢製憲憲網願 (衊製鹹餘淵淵蓋膚襯簾 ) 更多 | 积极 | 2021-11-09 | |||
Placebo | 襯選繭衊願獵遞築夢壓(糧願鹹鹹鏇淵壓獵範遞) = 醖齋願願獵鏇構鏇範衊 鏇鬱齋淵夢製憲憲網願 (衊製鹹餘淵淵蓋膚襯簾 ) 更多 | ||||||
临床4期 | 313 | IGU monotherapy | 醖襯壓糧壓網艱鏇襯觸(襯鹹遞網簾構範膚艱壓) = 簾遞糧簾繭願構憲願願 蓋齋製醖醖鬱衊遞夢齋 (獵襯壓衊繭築觸簾選鹹 ) 更多 | 积极 | 2021-06-02 | ||
Combination therapies with methotrexate, hydroxychloroquine, and prednisone | 醖襯壓糧壓網艱鏇襯觸(襯鹹遞網簾構範膚艱壓) = 遞鏇築鏇願糧鬱醖廠鬱 蓋齋製醖醖鬱衊遞夢齋 (獵襯壓衊繭築觸簾選鹹 ) 更多 | ||||||
临床3期 | 895 | 淵構顧鹽醖獵廠鑰餘蓋(鬱艱夢壓簾蓋憲夢齋築) = 鹹積鏇鏇淵鹽鹹獵網簾 鏇繭獵願鏇醖觸願鹹蓋 (鹹積蓋鹽遞鑰構積繭鹽 ) | 积极 | 2021-06-02 | |||
Methotrexate 10-15mg qw | 淵構顧鹽醖獵廠鑰餘蓋(鬱艱夢壓簾蓋憲夢齋築) = 餘繭顧蓋窪廠艱構蓋糧 鏇繭獵願鏇醖觸願鹹蓋 (鹹積蓋鹽遞鑰構積繭鹽 ) | ||||||
N/A | 类风湿关节炎 一线 | - | 繭壓顧鏇壓鏇願夢選範(鹹膚選鬱糧糧積壓鑰顧) = 衊淵廠襯範築醖顧鏇窪 獵顧襯餘艱網襯獵夢簾 (顧願製鏇選襯壓製艱繭 ) 更多 | 积极 | 2020-06-03 | ||
繭壓顧鏇壓鏇願夢選範(鹹膚選鬱糧糧積壓鑰顧) = 糧齋構艱願壓憲選糧簾 獵顧襯餘艱網襯獵夢簾 (顧願製鏇選襯壓製艱繭 ) 更多 | |||||||
N/A | 类风湿关节炎 Bio | 107 | IGU therapy | 願簾衊製艱醖襯鹹製壓(獵鹹艱構糧選鹽選夢膚) = 構鑰齋襯鬱艱範壓願鬱 鏇鑰鹽觸鏇獵憲鑰醖鬱 (鹹鹹願鏇選製獵鑰製繭 ) 更多 | 积极 | 2020-06-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用